ArticleScientific reports2025
Impact of the COVID-19 pandemic on the epidemiology and molecular features of Pseudomonas aeruginosa bloodstream infections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pseudomonas aeruginosa (PA) bloodstream infections (BSIs) are severe, life-threatening events. PA success involves a complex interplay between virulence, antimicrobial resistance and epidemicity. This study examines the impact of COVID-19 pandemic on PA-BSI characteristics. Seventy-eight bacteraemic PA isolates were collected in two periods: pre-COVID 2015-2018 (48 PA) and post-COVID 2022-2023 (30 PA). An increase in non-susceptibility rates was found in post-COVID period, noteworthy for gentamicin, netilmicin and multidrug-resistance, although extensively drug resistant/difficult-to-treat (XDR/DTR) isolates were only detected in pre-COVID period. All isolates were cefiderocol-susceptible, but resistance to novel cephalosporin-inhibitor combinations and colistin was identified in pre-COVID period. Carbapenem-non-susceptible PA persisted around 20%, associated with OprD alterations and one pre-COVID-isolate harboured bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.